Payment overview · 2025
General Payments
$2,629.53
137 reported records · 25 companies
Healthcare provider profile · identity verified
Dora Perez, MS, ANP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Adult Health · NEW YORK, NY · NPI 1467852251
Verified facts
What the public records show
CMS Open Payments records show Dora Perez, MS, ANP received $2,629.53 in general payments during 2025 across 137 reported records.
ABBVIE INC. accounted for 12.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ubrelvy by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rytary by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $340.45 | 12.9% | 12 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $317.30 | 12.1% | 19 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $254.95 | 9.7% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $253.91 | 9.7% | 13 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $163.79 | 6.2% | 22 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$143.82 | 5.5% | 10 | 2025 |
| InSightec,Inc | Unresolved — no canonical attribution shown | $107.63 | 4.1% | 2 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $97.71 | 3.7% | 6 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $92.74 | 3.5% | 5 | 2025 |
| SERVIER PHARMACEUTICALS LLC | Unresolved — no canonical attribution shown | $90.56 | 3.4% | 5 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$83.51 | 3.2% | 2 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $68.23 | 2.6% | 4 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $67.89 | 2.6% | 4 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $66.51 | 2.5% | 4 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$65.63 | 2.5% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $64.57 | 2.5% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $61.73 | 2.4% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $51.59 | 2.0% | 3 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $51.31 | 1.9% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $48.27 | 1.8% | 3 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $36.84 | 1.4% | 2 | 2025 |
| Novocure Inc. | Unresolved — no canonical attribution shown | $36.80 | 1.4% | 2 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.03 | 1.2% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $18.63 | 0.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.13 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,584.53 | 136 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| General - DBS Normalized: general dbs |
Device | Boston Scientific Corporation | $254.95 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $225.16 | 11 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $214.16 | 5 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $163.79 | 22 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $143.82 | 10 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $108.29 | 7 | 2025 |
Source payment records
|
|||||
| Exablate Normalized: exablate |
Device | InSightec,Inc | $107.63 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $92.74 | 5 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $82.96 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $78.22 | 4 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $70.61 | 4 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $68.23 | 4 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $67.89 | 4 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $66.51 | 4 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $65.24 | 4 | 2025 |
Source payment records
|
|||||
| INFINITY Normalized: infinity |
Device | Abbott Laboratories | $64.57 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $62.84 | 4 | 2025 |
Source payment records
|
|||||
| ZEMBRACE SYMTOUCH Normalized: zembrace symtouch |
Drug | Tonix Medicines, Inc. | $61.73 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $58.56 | 3 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $55.14 | 3 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $51.59 | 3 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $51.31 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $48.27 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $48.27 | 3 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $48.07 | 3 | 2025 |
Source payment records
|
|||||
| PERCEPT PC BRAINSENSE Normalized: percept pc brainsense |
Device | Medtronic, Inc. | $45.00 | 1 | 2025 |
Source payment records
|
|||||
| STEALTHSTATION S8 PLATFORM Normalized: stealthstation s8 platform |
Device | Medtronic, Inc. | $38.51 | 1 | 2025 |
Source payment records
|
|||||
| QALSODY Normalized: qalsody |
Drug | Biogen, Inc. | $36.84 | 2 | 2025 |
Source payment records
|
|||||
| SPINRAZA Normalized: spinraza |
Biological | Biogen, Inc. | $36.84 | 2 | 2025 |
Source payment records
|
|||||
| Optune Gio Normalized: optune gio |
Device | Novocure Inc. | $36.80 | 2 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $31.62 | 2 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $31.03 | 2 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $28.75 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| Voranigo Normalized: voranigo |
Drug | SERVIER PHARMACEUTICALS LLC | $17.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
30 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone Hcl | Oxycodone Hcl | 236 | 107 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 172 | 71 |
| Gabapentin | Gabapentin | 114 | 34 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 100 | 65 |
| Naloxone Hcl | Naloxone Hcl | 86 | 77 |
| Alprazolam | Alprazolam | 63 | 26 |
| Baclofen | Baclofen | 62 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 59 | 33 |
| Pregabalin | Pregabalin | 52 | 19 |
| Clonazepam | Clonazepam | 46 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 19 |
| Tramadol Hcl | Tramadol Hcl | 44 | 22 |
| Morphine Sulfate Er | Morphine Sulfate | 42 | 20 |
| Belbuca | Buprenorphine Hcl | 31 | 19 |
| Carisoprodol | Carisoprodol | 30 | suppressed |
| Rytary | Carbidopa/Levodopa | 30 | 12 |
| Hydromorphone Hcl | Hydromorphone Hcl | 28 | 19 |
| Lorazepam | Lorazepam | 28 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Lidocaine | Lidocaine | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | 11 |
| Diazepam | Diazepam | 16 | suppressed |
| Oxycontin | Oxycodone Hcl | 16 | suppressed |
| Ubrelvy | Ubrogepant | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Xtampza Er | Oxycodone Myristate | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Neupro | Rotigotine | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,629.53 · 137 records | ABBVIE INC. | AJOVY, AUSTEDO XR, BOTOX, Briviact, CREXONT, EPIDIOLEX, Exablate, Fintepla, General - DBS, INBRIJA, INFINITY, INGREZZA, Leqembi, Motpoly XR, NUPLAZID, NURTEC ODT, Nayzilam, Optune Gio, PERCEPT PC BRAINSENSE, QALSODY, QULIPTA, Radicava, Rystiggo, SPINRAZA, STEALTHSTATION S8 PLATFORM, UBRELVY, VALTOCO, VYALEV, VYEPTI, VYVGART, VYVGART HYTRULO, Voranigo, Xeomin, ZAVZPRET, ZEMBRACE SYMTOUCH, Zilbrysq | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ubrelvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error